Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04370704
Other study ID # INCAGN 2385-201
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 27, 2020
Est. completion date August 4, 2025

Study information

Verified date April 2024
Source Incyte Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 61
Est. completion date August 4, 2025
Est. primary completion date August 4, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Phase 1 Parts 1-4): Participants with locally advanced or metastatic solid tumors (locally advanced disease must not be amenable to resection with curative intent) that have failed available therapies, including anti-PD-(L)1 therapy if applicable, that are known to confer clinical benefit, or who are intolerant to, or ineligible for standard treatment. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance. - Phase 2, Cohort A: 1. Participant with histologically confirmed unresectable/metastatic melanoma, whose disease failed prior anti-PD-(L)1 therapy (alone or as part of a combination) and meeting one of the following criteria: - Participant who failed prior adjuvant anti-PD-(L)1 therapy for resectable melanoma must have received prior anti-PD-(L)1 for = 6 weeks and experienced disease progression while still on active adjuvant therapy containing anti-PD-(L)1, or participant who had early relapse occurring < 24 weeks after end of adjuvant anti-PD-(L)1 therapy. Progressive disease must be ascertained by confirmatory biopsy collected at baseline. - Participant whose unresectable/metastatic disease progressed while on or within < 24 weeks of completion of anti-PD-(L)1 for inresectable/metastatic melanoma. Progressive disease must have been confirmed by imaging = 4 weeks after evidence of initial disease progression. 2. Participant must have received no more than 2 prior lines of therapy for melanoma and at least one prior regimen must have contained anti-PD-(L)1 therapy (alone or as part of a combination) either in the adjuvant and/or advanced/metastatic setting. 3. Participants must have had known BRAF V600 mutation status per local institutional testing standards. 4. Participants must have fresh biopsy available after completing prior PD-(L)1 therapy or be willing and able to safely undergo pretreatment tumor biopsies (core or excisional). Determination of whether participants can safely undergo biopsy should be made by the treating physician in consultation with the individual performing the biopsy. 5. Participant must have at least 1 measurable tumor lesion per RECIST v1.1. - Phase 2, Cohort B: 1. Participant with previously untreated, histologically confirmed Stage III (unresectable) or IV melanoma per the American Joint Committee on Cancer v8 staging system. 2. Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma. 3. Participants must have had known BRAF V600 mutation status per local institutional testing standards. 4. Participants must have fresh biopsy available or be willing and able to safely undergo pretreatment tumor biopsies (core or excisional). Determination of whether participants can safely undergo biopsy should be made by the treating physician in consultation with the individual performing the biopsy. - Phase 2 (Cohorts A and B): Participant must have at least 1 measurable tumor lesion per RECIST v1.1. - ECOG performance status 0 or 1. - Willingness to avoid pregnancy or fathering children Exclusion Criteria: - Laboratory and medical history parameters outside the protocol-defined range. - Known hypersensitivity or severe reaction to any component of the study drugs or formulation components ) within 14 days before study Day 1. - Participant who had prior treatment with a LAG-3 or TIM-3 targeted agent. Phase 1: (Parts 1-4): - Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study treatment: 1. =28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational agents or devices. For investigational agents with long half-lives (eg, > 5 days), enrollment before the fifth half-life requires medical monitor approval. 2. Administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before study Day 1. - Phase 2: - Cohort A: Participant who has discontinued anti-PD-(L)1 therapy due to toxicity or other reasons unrelated to toxicity, then subsequently experienced disease progression. - Cohort A: Participant who had experienced objective response (PR/CR) and had stopped anti-PD-(L)1 therapy due to maximal benefit. - Cohort A: Participant with multiple metastases that achieved mixed tumor response to prior anti-PD-(L)1 therapy (such as isolated progressive lesion in a context of PR/CR or SD for other lesions) or achieved overall disease progression based only on a single new lesion. - Cohort B: Participant who has or has had uveal melanoma. - Receipt of anticancer therapy (immunotherapy, chemotherapy, targeted therapy or hormonal therapy) within 21 days of the first administration of study treatment, with the exception of localized radiotherapy. - Palliative radiation therapy administered within 1 week of first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment. - If participant received major surgery, then they must have recovered adequately from toxicities and/or complications from the intervention before starting study treatment. - Treatment-related toxicity related to prior therapy that has not recovered to = Grade 1 (with the exception of alopecia and anemia not requiring transfusional support), unless approved by the medical monitor. - History of immune-related toxicity during prior checkpoint inhibitor therapy for which permanent discontinuation of therapy is recommended (per product label or consensus guidelines), OR any immune-related toxicity requiring intensive or prolonged immunosuppression to manage (with the exception of endocrinopathy that is well controlled on stable dose of replacement hormones such as hypothyroidism or adrenal insufficiency, or Grade 3 rashes that resolved with topical therapy or asymptomatic lipase elevations that do not require treatment interruption or uveitis that resolved with steroid drops). - Has an active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 14 days before the first dose of study treatment. - Receiving chronic systemic corticosteroids (> 10 mg/day of prednisone or equivalent). - Active infections requiring systemic antibiotics, or antifungal or antiviral treatment within 7 days before first dose of study treatment. - History of organ transplant, including allogeneic stem cell transplantation. - Evidence of interstitial lung disease or active, noninfectious pneumonitis. - Known active HBV or HCV infection or risk of reactivation of HBV or HCV. - Participants who are known to be HIV-positive . - Known active brain or CNS metastases including carcinomatous meningitis. - Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy after treatment with curative intent. - Participants with impaired cardiac function or clinically significant cardiac disease - History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful. - Women who are pregnant or breastfeeding. - Receipt of a live vaccine within 30 days of planned start of study treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
INCAGN02385
INCAGN02385 administered intravenously
INCAGN02390
INCAGN02390 administered intravenously
INCMGA00012.
INCMGA00012 administered intravenously

Locations

Country Name City State
Australia Flinders Medical Centre Bedford Park South Australia
Australia Box Hill Hospital Box Hill Victoria
Australia Greenslopes Private Hospital Brisbane Queensland
Australia One Clinical Research Nedlands Western Australia
Australia Melanoma Institute Australia Wollstonecraft New South Wales
United States Cancer Center For Blood Disorders A Division of American Oncology Partners P.A Bethesda Maryland
United States John Theurer Cancer Center, Hackensack University Medical Center Hackensack New Jersey
United States Penn State Hershey Cancer Institute Hershey Pennsylvania
United States Carolina Bio Oncology Huntersville North Carolina
United States University of Iowa Iowa City Iowa
United States The Angeles Clinic and Research Institute Los Angeles California
United States University of Miami Sylvester Comprehensive Cancer Center Miami Florida
United States Nyu Langone Laura and Isaac Perlmutter Cancer Center New York New York
United States Hillman Cancer Center Pittsburgh Pennsylvania
United States Washington University Saint Louis Missouri
United States University of Washington-Seattle Cancer Care Alliance Seattle Washington
United States H Lee Moffitt Cancer Center and Research Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Incyte Corporation

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phases 1 & 2: Participants with treatment-emergent adverse events (TEAEs) TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug 28 days after end of study approximately 24 months
Primary Phase 2 Cohort A and B: Objective Response Rate (ORR) Defined as the percentage of participants having a Complete Response or Partial Response, will be determined by investigator assessment of radiographic disease assessments per RECIST v1.1. Every 8 weeks for first 12 months, and every 12 weeks until disease progression; approximately 24 months
Primary Phase 2 Cohort A and B: Duration of Response (DOR) Defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression, as determined by investigator assessment of radiographic disease per RECIST v1.1, or death from any cause, if occurring sooner than progression. Every 8 weeks for first 12 months, and every 12 weeks until disease progression; approximately 24 months
Primary Phase 2 Cohort A and B: Disease Control Rate (DCR) Defined as percentage of participants having CR, PR, or SD as best on-study response. Every 8 weeks for first 12 months, and every 12 weeks until disease progression; approximately 24 months
Primary Phase 2 Cohort A and B: Progression-free Survival (PFS) Defined as the time from date of first dose of study treatment until the earliest date of disease progression, as determined by investigator assessment of objective radiographic disease per RECIST v1.1 Every 8 weeks for first 12 months, and every 12 weeks until disease progression; approximately 24 months
Secondary Phase 1 : Objective Response Rate Defined as the percentage of participants having a Complete Response or Partial Response, will be determined by investigator assessment of radiographic disease assessments per RECIST v1.1. Every 8 weeks for first 12 months, and every 12 weeks until disease progression; aprroximately 24 months
Secondary Phase 1 : Progression Free Survival Defined as the time from date of first dose of study treatment until the earliest date of disease progression, as determined by investigator assessment of objective radiographic disease per RECIST v1.1. Every 8 weeks for first 12 months, and every 12 weeks until disease progression; aprroximately 24 months
Secondary Phase 1: Disease Control Rate (DCR) Defined as percentage of participants having CR, PR, or SD as best on-study response Every 8 weeks for first 12 months, and every 12 weeks until disease progression; approximately 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study